The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.b

ARDS - Acute lung injury

The role of G/GM CSF in promotig bleomycin pulmonary toxicity is unclear (PMID 30319063)

Publications

Doig C, Cooke R, Chua C, Leung T

Acute respiratory distress syndrome precipitated by granulocyte colony-stimulating factor in undiagnosed Pneumocystis jirovecii pneumonia.

BMJ case reports. 2022;15(2)

Shalata W, Waichenberg L, Massalha I, Dudnik Y, Rouvinov K, Yakobson A

Pulmonary toxicity following administration of granulocyte colony-stimulating factor during chemotherapy for breast cancer: a case report and literature review.

Anti-cancer drugs. 2021;32(10):1142-1145

Kudlak K, Demuro JP, Hanna AF, Brem H

Acute lung injury following the use of granulocyte-macrophage colony-stimulating factor.

International journal of critical illness and injury science. 2013;3(4):279-81

Wetzko K, Blechschmidt M, Hölig K, Poppe-Thiede K, Ganepola S, Fischbach R, Ordemann R, Laniado M, Schulte-Hubbert B, Schuler M, Cotta L, Braumann D, Ehninger G, Kroschinsky F

Pulmonary adverse events in unrelated donors of peripheral blood stem cells.

Transfusion medicine (Oxford, England). 2013;23(1):69-71

Shi B, Liu L, Ye L

Lung injury in a leukemia patient during mobilization of peripheral blood stem cells using granulocyte colony-stimulating factor alone.

Annals of hematology. 2012;91(3):469-70

Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G, Baldomero H, Niederwieser D, Apperley JF, Gratwohl A

Severe events in donors after allogeneic hematopoietic stem cell donation.

Haematologica. 2009;94(1):94-101

Takatsuka H, Takemoto Y, Mori A, Okamoto T, Kanamaru A, Kakishita E

Common features in the onset of ARDS after administration of granulocyte colony-stimulating factor.

Chest. 2002;121(5):1716-20

Azoulay E, Attalah H, Harf A, Schlemmer B, Delclaux C

Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data.

Chest. 2001;120(5):1695-701

Couderc LJ, Stelianides S, Frachon I, Stern M, Epardeau B, Baumelou E, Caubarrere I, Hermine O

Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases.

Respiratory medicine. 1999;93(1):65-8

Verhoef G, Boogaerts M

Treatment with granulocyte-macrophage colony stimulating factor and the adult respiratory distress syndrome.

American journal of hematology. 1991;36(4):285-7

Miniero R, Madon E, Artesani L, Busca A, Sandri A, Aglietta M, Ramenghi U

Acute pulmonary failure after the first administration of recombinant human granulocyte-macrophage colony-stimulating factor.

Leukemia. 1992;6(4):352-3